香港, 2025年4月22日 - (亚太商讯 via SeaPRwire.com) - 近年来，随着核药顶层设计出台及配套支持政策陆续落地，国内核医药产业迎来黄金发展期。据BCC Research数据分析，全球核医药市场将从2023年126亿美元增长到2029年底的210亿美元，在2024年至2029年的预测期内的复合年增长率(CAGR)为8.29%。而专注于放射治疗和核医学的市场情报机构Medraysintell则预期2030年全球核药市场将达约300亿美元。作为国内核药龙头，中国同辐（01763.HK）近日披露了截至12月31日止的2024年度报告，中国同辐在2024年实现了营收、净利的显著增长，在业绩层面交上了令人满意的答卷，在核药研发方面也展现出强大的技术转化能力。业绩逐年提升 核医疗装备成新引擎从财务数据来看中国同辐在2024年实现营业收入75.75亿元，同比增长14.2%；净利润8.80亿元，同比增长13.3%。从分部业务来看，各领域全面开花。核药业务作为公司的核心支柱，实现收入41.68亿元，占据总营收的55%。其中，显像诊断及治疗用放射性药物收入同比增长4.1%，医药中心全国布局成效显著，锝标药物收入同比增长8.7%。呼气检测业务持续保持稳定的高市场占有率，实现收入23.50亿元，同比增长1.1%。值得注意的是，2024年中国同辐加速推进高端放疗设备国产化，核医疗装备及相关服务成为增长新引擎，营收达到12.23亿元，同比增长31.0%。全新一代Precision放射治疗计划系统成功获批医疗器械注册证，全球首台螺旋断层放疗系统Tomo C运至山东省肿瘤医院装机并入选2024年两部委（工业和信息化部╱国家卫生健康委）高端医疗装备推广应用项目和《天津市首台（套）重大技术装备推广应用指导目录》（2024版），年销售持续领跑国内市场。放射源产品业务同样表现出色，实现收入7.16亿元，同比增长22.2%。伽玛刀源、探伤源持续保持稳定的高市场占有率，中核秦同顺利取得甲级辐射安全许可证，钴-60放射源生产线交付产品200万居里。40年核技术深耕 构筑全产业链护城河作为中核集团核技术应用产业发展主体，中国同辐深耕行业逾40年，更通过"6+N"产业布局形成了核素、核药、核医疗装备、核医学整体解决方案、放射源及应用、辐照应用等核心业务协同发展的生态体系。报告期内，公司新获专利授权224项，累计有效专利达969项，研发投入强度持续保持行业领先。在核药研发领域，中国同辐展现出强大的技术转化能力。氟[18F]化钠注射液的获批上市填补了国内骨显像PET诊断显像剂市场空白；碘[131I]-MIBG注射液III期临床收尾，该药物上市后将为嗜铬细胞瘤和神经母细胞瘤等神经内分泌肿瘤提供新的诊断方式。值得关注的是，公司前瞻性布局诊疗一体化药物，镥[177Lu]氧奥曲肽注射液研发进展顺利，标志着从单纯诊断向精准诊疗的战略升级。除了稳住核药的基本盘外，公司对于核医疗装备的重视程度逐渐提升。从近年销售数据来看，核医疗装备收入稳步上升。2024年全新一代伽马刀获批，融合CBCT图像引导、六维床校正等智能技术，治疗效率提升30%。在甲类大型医用设备市场，中国同辐通过控股子公司中核安科锐占据绝对主导地位，今年2月，国家卫健委发布的2024年第二轮甲类大型医用设备准予许可名单中28台高端放疗设备有19台来自该公司，市场占有率达68%。值得注意的是，公司在钴60立体定向治疗系统等领域的突破，也推动着放疗设备国产化替代进程。面对核药市场的爆发式增长，中国同辐加速医药中心全国网络布局持续拓展。2024年，新增兰州正电子药物生产线，累计投产23条；新增福州锝药生产线，累计投产27条。中国同辐建成国内首条万居里级镥[177Lu]生产线及千条级锗镓[68Ge-68Ga]发生器产线，实现高端核素国产化突破。值得关注的是，中国同辐通过"母子协同"模式，打造了层次分明的创新生态。2024年，其子公司中核海得威（呼气检测）、中核高通（核素）企业获评国家级专精特新"小巨人"，至此中国同辐旗下专精特新企业总数达18家。其中，中核海得威以"药盒+仪器"一体化方案占据呼气检测市场主导地位，中核高通则通过"核素-药物-装备"全链条布局，成为核技术应用领域标杆。这种"航母战斗群"式的创新体系，为公司长期增长提供了可持续动力。全球化布局拓展发展空间作为中核集团面向人民生命健康科技进军的主力和先进核科技成果转化的主通道，中国同辐响应集团"整体-协同"的国际化战略以及国家"一带一路"倡议，大力推进国际化战略，不断拓展海外市场。2024年实现出口收入达6.27亿元，产品远销巴西、秘鲁、尼日利亚等数十个国家和地区。今年初更是成功签署孟加拉百万居里设计装源量辐照站设备供应合同，这是继2024年中标孟加拉核农业研究院设计装源量百万居里伽马辐照站项目后，又一辐照站设备供应项目落地。该辐照站建成启用后主要服务于孟加拉医疗领域产品的辐照灭菌，将显著提升当地医疗产品质量水平及生产加工能力，助力孟加拉医疗产业发展，造福当地民生。在尼日利亚，公司成功签约核医疗设备整体供应项目，实现集团核医疗装备整体供应项目首次成功落地。此外，公司还积极拓展东盟市场，放药配套冷药成功出口泰国；亦与巴西多个主体签署战略合作协议，支撑国家原子能机构与巴西签署核技术应用领域战略合作备忘录。结语在政策支持与市场需求持续释放的背景下，中国同辐表示将围绕"健康中国"战略框架,聚焦"国之所需"，进一步深化核医药与高端装备的协同发展。据其2025年规划，秦山同位素基地、夹江放射源基地一期及华北医药基地一期等重点项目将按节点推进，涉及核素生产、放射源制造及医药供应链布局。同时，中国同辐将通过智慧核医学项目迭代，提升数字化诊疗服务能力，计划年内上线不少于3个智能系统。国际化层面，中国同辐将延续"一带一路"沿线市场拓展策略，依托现有辐照站设备出口、核医疗装备整体解决方案输出等业务模式，重点聚焦南美、东南亚、中东、北非等区域市场的合作，未来或通过本地化合作进一步提升全球市场渗透率。公司管理层表示，2025年中国同辐将持续加强科技创新，健全现代产业体系，加快培育发展新质生产力，不断增强核心功能，提升核心竞争力，加快建成国际知名的同位素与辐射技术应用产品和服务供应集团。 Copyright 2025 亚太商讯 via SeaPRwire.com.

HONG KONG, Apr 22, 2025 - (ACN Newswire via SeaPRwire.com) – In recent years, with the launch of top-level design for nuclear medicines and the implementation of supporting policies, the domestic nuclear medicine industry has ushered in a golden period of development. According to the data analysis of BCC Research, there will be a growth in the global nuclear medicine market from $12.6 billion in 2023 to $21 billion by the end of 2029, with a compound annual growth rate (CAGR) of 8.29% during the forecast period from 2024 to 2029. Meanwhile, Medraysintell, a market intelligence agency specializing in radiotherapy and nuclear medicine, predicts that there will be a growth of about $30 billion in the global nuclear medicine market in 2030.As a leading nuclear medicine company in China, CIRC (01763.HK) recently disclosed its annual report for 2024 as of December 31st. In 2024, CIRC achieved a remarkable growth in revenue and net profit, which not only delivered a satisfactory answer on the performance level, but also showed a strong technical transformation capability in nuclear medicine research and development.Year-by-year growth facilitated nuclear medical equipment to become a new engineAccording to the financial data, CIRC achieved revenue of RMB 7.575 billion in 2024, with a year-on-year increase of 14.2%, and the net profit of RMB 880 million, with a year-on-year increase of 13.3%.From the perspective of branch business, all fields have blossomed in an all-round way. As the core pillar of the company, the nuclear medicine business achieved revenue of RMB 4.168 billion, accounting for 55% of the total revenue. Among them, the income of imaging diagnosis and therapeutic radiopharmaceuticals increased by 4.1% year-on-year, and the distribution of medical centers all over the country achieved remarkable results. The income of Technetium-labeled medicines increased by 8.7% year-on-year. The breath test business continued to maintain a stable high market share, achieving revenue of RMB 2.35 billion, by a year-on-year increase of 1.1%.It is worth noting that in 2024, CIRC accelerated the localization of high-end radiotherapy equipment, and nuclear medical equipment and related services became the new engine of growth, with revenue reaching RMB 1.223 billion, a year-on-year increase of 31.0%. The new generation of Precision radiation therapy planning system was successfully approved for medical device registration certificate, and the world’s first spiral tomotherapy system, Tomo C, was delivered to Shandong Cancer Hospital for installation, which was successfully selected intothe 2024 high-end medical equipment promotion and application project of two ministries and commissions (Ministry of Industry and Information Technology/National Health Commission) and Tianjin First (Set) Major Technical Equipment Promotion and Application Guidance Catalog (Version 2024), with sales during the year leading in the domestic market.CIRC recorded RMB 716.1 million in revenue from radioactive source products, representing a year-on-year increase of 22.2%. Gamma knife source and non-destructive testing radioactive source continued to maintain a stable and high market share. CNNC Qinshan Isotope successfully obtained the Class A radiation safety license, and the cobalt-60 radioactive source production line delivered 2 million curies.40-year solid accumulation in nuclear technology laid a solid foundationAs the main body of the nuclear technology application industry of CNNC, CIRC has been accumulated in the industry for over 40 years, forming a “6+N” industrial layout with six major businesses as the core, including nuclides, nuclear medicines, nuclear medical equipment, integrated solution for nuclear medicine, radioactive source and application, and irradiation application. During the Reporting Period, CIRC achieved 224 patent authorizations, with a total of 969 valid patents, and continued to maintain the leading position of the R&D investment intensity in the industry.In the field of nuclear medicine research and development, CIRC has demonstrated a strong technical capability from research results turned into technologies. Sodium fluorine-18 injection obtained the drug registration certificate from the National Medical Products Administration and was approved for marketing, filling the market gap of PET diagnostic imaging agent in the field of bone imaging in China. Iodine-131-MIBG injection is close to the end of Phase III clinical trial. After the drug is launched, it will provide a new diagnostic method for neuroendocrine tumors such as pheochromocytoma and neuroblastoma. It is worth noting that CIRC has proactively laid out integrated diagnosis and treatment drugs, and the research and development of Lutetium-177oxyoctreotide injection is progressing smoothly, marking a strategic upgrade from simple diagnosis to precise diagnosis and treatment.In addition to stabilizing the base of nuclear medicine, CIRC has gradually increased its emphasis on nuclear medical equipment. According to the sales data in recent years, the income of nuclear medical equipment has steadily increased. In 2024, a new generation of Gamma Knife was approved, which integrated CBCT image guidance, six-dimensional bed auto-correction, and other intelligent technologies, and the treatment efficiency was improved by 30%. In the Class A large-scale medical equipment market, CIRC occupies an absolute dominant position through its holding subsidiary, CNNC ACCURAY. In February this year, 19 of the 28 high-end radiotherapy equipment in the second round of Class A large-scale medical equipment licensing list released by the National Health Commission came from CNNC ACCURAY, accounting for 68% of the market. It is worth noting that the breakthroughs in the fields of Cobalt-60-based Stereotactic Therapy System also promote the localization of radiotherapy equipment.Facing the explosive growth of the nuclear medicine market, CIRC Accelerated Pharmaceutical Center continues to expand its nationwide network layout. In 2024, a new positron emission drug production line has been added in Lanzhou, with a total of 23 lines put into operation; Newly added Fuzhou Technetium Drug Production Line, with a total of 27 units put into operation. CIRC has built the first 10,000 Curie level lutetium-177 production line and a thousand level germanium-gallium [68Ge-68Ga] generator production line in the country, achieving a breakthrough in the localization of high-end nuclides.It is worth noting that CIRC has created a hierarchical innovation ecosystem through the "Parent-Subsidiary Collaboration" model. In 2024, its subsidiaries, CNNC HEADWAY (breath test) and CNNC Chengdu Gaotong (nuclide), were awarded the national level specialized, refined, and new "little giants" enterprise, bringing the total number of specialized, refined, and new enterprises under CIRC to 18. Among them, CNNC HEADWAY dominates the breath testing market with its integrated solution of "medicine box+instrument", while CNNC Chengdu Gaotong has become a benchmark in the field of nuclear technology application through its full chain layout of "Nuclide-Drug-Equipment". This innovative system, resembling an "Aircraft carrier battle group", provides sustainable momentum for the company's long-term growth.Expanding Development Space with Globalization LayoutAs the main force of CNNC Group's march towards people's life and health science and technology and the main channel for the transformation of advanced nuclear science and technology achievements, CIRC responds to the Group's "Overall&Coordination" internationalization strategy and the national "the Belt and Road" initiative, vigorously promotes the internationalization strategy and constantly expands overseas markets. By 2024, the export revenue will reach RMB 627 million, and the products will be exported to dozens of countries and regions such as Brazil, Peru, and Nigeria.At the beginning of this year, we successfully signed a contract for the supply of equipment for a million curies design source gamma irradiation station in Bangladesh. This is another equipment supply project for irradiation stations that has landed after winning the bid for the Bangladesh Institute of Nuclear Agriculture's design source gamma irradiation station project in 2024. After its completion and operation, the irradiation station will mainly serve the irradiation sterilization of medical products in Bangladesh, significantly improving the quality level and production processing capacity of local medical products, assisting the development of Bangladesh's medical industry, and benefiting local people's livelihoods.In Nigeria, CIRC successfully signed a contract for the overall supply of nuclear medical equipment, achieving the first successful landing of the Group's nuclear medical equipment overall supply project. In addition, CIRC actively expands into the ASEAN market and successfully exports cold chain drugs to Thailand; We have also signed strategic cooperation agreements with multiple entities in Brazil to support the signing of a memorandum of understanding on strategic cooperation in the field of nuclear technology applications between the National Atomic Energy Agency and Brazil.ConclusionAgainst the backdrop of policy support and sustained market demand, CIRC stated to focus on the "Do as the Demard of the Country" and further deepen the coordinated development of nuclear medicine and high-end equipment around the "Healthy China" strategic framework. According to its 2025 plan, key projects such as Qinshan Isotope Base, Phase I of Jiajiang Radioactive Source Base, and Phase I of North China Pharmaceutical Base will be promoted according to milestones, involving nuclide production, radioactive source manufacturing, and pharmaceutical supply chain layout. At the same time, CIRC will enhance its digital diagnosis and treatment service capabilities through the iteration of smart nuclear medicine projects, and plans to launch no less than 3 intelligent systems within this year.At the international level, CIRC will continue the market expansion strategy along the "the Belt and Road", rely on the existing business models such as radiation station equipment export, nuclear medical equipment overall solution output, focus on the cooperation in South America, Southeast Asia, the Middle East, North Africa and other regional markets, and further improve the global market penetration rate in the future or through localized cooperation.The management of the Company stated that in 2025, CIRC will continue to strengthen technological innovation, improve the modern industrial system, accelerate the cultivation and development of new quality productivity, continuously enhance core functions, improve core competitiveness, and accelerate the establishment of an internationally-renowned supply group of technology, product and service in isotope and radiation. Copyright 2025 ACN Newswire via SeaPRwire.com.

Luxembourg, Apr 21, 2025 - (ACN Newswire via SeaPRwire.com) - Moolec Science SA (NASDAQ:MLEC) ("The Company" or "Moolec"), a science-based food ingredient company focused on producing animal proteins and nutritional oils in plants, today announced that it has entered into a Business Combination Agreement (the "BCA") with Bioceres Group Limited ("Bioceres Group") and other related entities in an all-stock transaction (the "Business Combination"). Subject to the terms and conditions of the BCA, which was signed on April 17, 2025, several parties will transfer their respective holdings in Bioceres Group, Nutrecon LLC ("Nutrecon"), and Gentle Technologies Corp ("Gentle Tech", and together with Bioceres Group and Nutrecon, the "Contributed Entities"), resulting in an enlarged corporate structure with Moolec as the parent company. In exchange, Moolec will issue a combination of up to 87 million newly issued shares and 5 million warrants to the shareholders of the Contributed Entities, as more fully described below in the Timing and Approvals section.Federico Trucco, Bioceres Group's board member and CEO of Bioceres Crop Solutions Corp commented: "The need to accelerate agricultural innovation to address current and future challenges, such as enhancing on-farm profitability and reducing environmental impact, is increasingly evident. Molecular farming, as exemplified by Moolec Science, offers a compelling solution to the challenge of balancing productivity and sustainability. For instance, what soybean yield technology can rival the direct production of 300kg of animal protein from a 3-ton-per-hectare crop?" He then finished: "Moolec's recent transformational transaction represents the kind of bold action needed to drive radical change in agriculture. Integrating technologies and capabilities, along with a holistic perspective on agricultural evolution, are essential for moving beyond incremental improvements. Scale and visibility, both of which are key aspects of this transaction, are crucial to achieving this goal. Bioceres is enthusiastic to be part of a larger, more ambitious Moolec, one that expands its focus from science in food ingredients to a comprehensive ‘cradle-to-cradle' approach."Juan Sartori, Founder and Chairman of Union Group remarked: "This is not just a strategic alignment of businesses, it's the creation of a new kind of company for the 21st century. By combining science, scale, and sustainability, Moolec is positioned to lead a global transformation in how we produce food, materials, and energy. I'm proud to support this vision and the exceptional teams bringing it to life."Following the closing of the Business Combination, Moolec will become uniquely positioned in the agricultural value-chain, with a powerful and validated technology discovery and development engine that can address in a cost-competitive way multiple upstream and downstream needs. Moolec's new value proposition will be centered around modifying or improving seeds and microbes to positively impact the way we utilize land and water resources, while preserving and/or improving human health.Alejandro Antalich, Chairman of Synbio Powerlabs® added: "This combination marks a defining moment for the bioeconomy. By integrating next-gen ingredients, biological ag solutions, and deep-tech manufacturing capabilities under one roof, we are building a company with unmatched scientific depth and commercial reach. Together, we aim to accelerate the shift toward a more sustainable and resilient food system, one that works in harmony with nature, rather than against it."As stated in their most recent annual reports, the companies and brands, which will be controlled or co-controlled by Moolec at the closing of the Business Combination, manage a portfolio of more than 800 patents (or patent applications) and over 550 product registrations, which translates into more than half a billion dollars of goods and services sold in their last fiscal year, to customers in more than 50 different countries.José López Lecube, CFO and Director of Moolec commented: "This transformative transaction marks a new stage for Moolec, positioning the company for growth within a broader organization that facilitates synergies on multiple levels. Becoming part of a larger organization will enable cost efficiencies and significant revenue increase as well as product portfolio diversification. It will also enlarge our investor base, providing the company with new stakeholders who support Moolec's new and more diversified business."Finally, as reported Mr. Gastón Paladini will step down as Chief Executive Officer (CEO), Director and Chairman of the Board, effective immediately following Moolec's Extraordinary General Meeting ("EGM") to be held on April 22, 2025.Key highlights:Ingredient Innovation: Moolec will continue to develop its flagship molecular farming products such as Piggy Sooy™ and GLASO™, while integrating Mycofood™ under the Eternal® brand from Nutrecon.Biological Ag Expansion: Through Bioceres Group, Moolec will now offer upstream technologies for regenerative agriculture, including biological inputs and climate-resilient seeds like Rizobacter®, ProFarm®, and the HB4® trait.Advanced R&D and Services: Leveraging expanded infrastructure, Moolec will offer R&D, CDMO, and regulatory services under the Agrality® and Synbio Powerlabs® brands, which are controlled or co-controlled by Bioceres Group and Nutrecon, respectively.Emerging Tech & Equipment: The Company will also expand its reach into emerging technologies for grain and biomass transformation, especially in the biomaterials space, as well as new concepts on farm equipment, integrating material science, electric mobility, and autonomy. These emerging opportunities are being pursued by Gentle Tech and Bioceres Group subsidiaries.Operational Synergies: The Business Combination is expected to result in significant cost synergies and an integrated management structure, which will be presented at or prior to closing of the Business Combination.Timing and ApprovalsThe Business Combination was unanimously approved by the Board of Directors of all the entities participating in the deal. It is expected to close during the second quarter of 2025 or thereafter, and it is subject to finalizing Moolec's reverse stock split process and re-domicile to the Cayman Islands among other customary closing conditions and regulatory approvals. This includes the approval by Moolec's shareholders at a special meeting of shareholders of proposals relating to the Business Combination. Given that the transaction was originally proposed by about 70% of Moolec's current shareholders, the Company expects strong shareholder support for the Business Combination approval.The Business Combination will be consummated through an equity exchange. Bioceres Group's shareholders will surrender their share ownership in Bioceres Group and will receive in exchange up to 80,590,280 shares of Moolec. The shareholders of 100% of Nutrecon and 50% of Gentle Tech will surrender their ownership in these two entities and will receive in exchange 6,475,000 shares of Moolec and 5,000,000 warrants of Moolec at a strike price of $2.00 per warrant, subject to adjustment based on the results of the reverse stock split process.The intrinsic value of the exchange ratio and the $2 strike price of warrants represent both a compelling premium to Moolec's current stock price, and a unique opportunity to assemble one of the most formidable public companies in the agricultural industry.Description of Contributed Entities and AssetsThe Contributed Entities consist of Bioceres Group and its subsidiaries, Nutrecon and its subsidiaries and Gentle Tech and its subsidiaries.Bioceres GroupBioceres Crop Solutions Corp. (NASDAQ: BIOX)Fully integrated provider of crop productivity solutions, including patented technologies for seeds and microbial agricultural inputs, as well as next generation crop nutrition and protection solutions. The company developed HB4® technology, which confers tolerance to climate changes in soybeans and wheat by allowing these crops to tolerate drought and soil salinity conditions. It also owns and licenses more than 570 products with approximately 750 patents and patent applications in the United States, Canada, Brazil, Argentina and other countries.Bioceres Tech Services (Agrality® & Inmet)Agrality® is a global agricultural services provider catering to agro-industrial companies worldwide. Their comprehensive service offerings encompass seed manufacturing and R&D, field-testing, and regulatory capabilities, ensuring their clients receive end-to-end solutions. Agrality's key assets include advanced seed production facilities, enabling high-quality seed development and production.Inmet specializes in the bio-transformation of agro-industrial residues, offering sustainable solutions for waste management in the agricultural sector. They utilize innovative technologies to convert agricultural waste into valuable products. Additionally, Inmet is involved in the production and assessment of bioplastics, contributing to the development of eco-friendly alternatives to conventional plastics.Nutrecon (Synbio Powerlabs®)Headquartered in Helsinki, Finland, Synbio Powerlabs® is an innovative early-stage biotechnology company specialized in research, development, and production of sustainable fungi-derived ingredients. With state-of-the-art laboratories and a pilot-to-industrial scale precision fermentation facility, the company operates uniquely as both a Research and Technology Organization ("RTO") and a Contract Development and Manufacturing Organization ("CDMO"). This dual role enables Synbio Powerlabs® to seamlessly bridge the gap between cutting-edge biotechnology research and real-world industrial applications, accelerating the commercialization of novel bio-based products. Its flagship product line, marketed under the Eternal® brand, features a diverse portfolio of high-quality, sustainable ingredients derived from fungi, serving multiple industries and applications.Gentle Tech (G-FAS & Gentle Farming)A frontier tech company developing sustainable, autonomous agricultural equipment. Focused on reducing environmental impact through innovations in materials science, information technologies, and alternative energy to maximize efficiency and minimize the carbon footprint. The business model includes G-FAS (selling ultra-light weight harvesting heads directly to farmers) and Gentle Farming (developing machinery for autonomy and intelligent management).Forward Looking StatementsThis press release contains "forward-looking statements." Forward-looking statements may be identified by the use of words such as "forecast," "intend," "seek," "target," "anticipate," "believe," "expect," "estimate," "plan," "outlook," and "project" and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements with respect to performance, prospects, revenues, and other aspects of the business of Moolec are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors, about which we cannot be certain. We cannot assure you that the forward-looking statements in this press release will prove accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others, changes in applicable laws or regulations, the possibility that Moolec may be adversely affected by economic, business and/or other competitive factors, costs related to the scaling up of Moolec's business and other risks and uncertainties, including those included under the header "Risk Factors" in Moolec's Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission ("SEC"), as well as Moolec's other filings with the SEC. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, you should not put undue reliance on these statements.Contact InformationPress & Media: comms@moolecscience.comInvestor Relations: ir@moolecscience.comSOURCE: Moolec Science SARelated Documents:Moolec Science Enters into Transformational Transaction Expanding Across Multiple Technology Platforms.pdf Copyright 2025 ACN Newswire via SeaPRwire.com.

卢森堡, 2025年4月21日 - (亚太商讯 via SeaPRwire.com) - Moolec Science SA（纳斯达克代码：MLEC）（以下简称“公司”或“Moolec”）是一家以科学为基础的食品原料公司，专注于在植物中生产动物蛋白和营养油。该公司今日宣布，已与Bioceres Group Limited（以下简称“Bioceres集团”）及其他相关实体签署了一项全股票交易的《业务合并协议》（以下简称“BCA”）。根据2025年4月17日签署的BCA条款和条件，若干方将转让其在Bioceres集团、Nutrecon有限责任公司（“Nutrecon”）以及Gentle Technologies Corp（“Gentle Tech”，与Bioceres集团和Nutrecon合称为“出资实体”）中的股份，从而形成一个以Moolec为母公司的扩展企业架构。作为交换，Moolec将向出资实体的股东发行最多8,700万股新股和500万份认股权证，具体情况将在下方“时间表与审批”部分进一步说明。Bioceres集团董事会成员兼Bioceres Crop Solutions Corp首席执行官Federico Trucco表示：“为了应对当前及未来的挑战，如提高农业盈利能力和降低环境影响，加快农业创新的需求日益明显。以Moolec Science为代表的分子农业，为在生产力与可持续性之间取得平衡提供了一种极具吸引力的解决方案。例如，哪种大豆产量技术能与每公顷3吨大豆直接生产300公斤动物蛋白相比拟？” 他进一步表示：“Moolec近期的这一变革性交易，正是推动农业根本性变革所需的大胆举措。整合技术与能力，以及从农业发展进行全面思考的视角，是突破渐进式改进、实现实质进展的关键。规模化与市场可见度——这两项本次交易的核心要素——对于实现这一目标至关重要。Bioceres非常高兴能够成为一个更大、更有雄心的Moolec的一部分，而这个Moolec的愿景，也已从食品原料领域的科学拓展为一个全面的‘从摇篮到摇篮’战略。”Union Group创始人兼董事长Juan Sartori表示：“这不仅是一次战略性的业务整合，更是一个面向21世纪全新公司形态的诞生。通过将科学、规模与可持续性结合，Moolec已具备引领全球在食品、材料与能源生产方式方面实现变革的潜力。我为能够支持这一愿景以及实现它的卓越团队而感到自豪。”在业务合并完成后，Moolec将在农业价值链中占据独特地位，拥有一套强大且经过验证的技术研发引擎，能够以具竞争力的成本满足多个上游和下游的需求。Moolec新的价值主张将围绕对种子和微生物的改良与优化，旨在改善人类对土地和水资源的利用方式，同时保护并促进人类健康。Synbio Powerlabs®董事长Alejandro Antalich补充道：“此次合并标志着生物经济发展的一个关键时刻。通过将下一代食品成分、生物农业解决方案以及深科技制造能力整合于一体，我们正在打造一家在科学深度和商业触达能力方面无可匹敌的企业。我们共同的目标是加速向一个更加可持续、更加具备韧性的食品系统转型——一个与自然和谐共生而非对抗的系统。”正如各公司在最新年度报告中所披露的那样，在本次业务合并完成后将由Moolec控股或共同控股的公司与品牌，共管理着超过800项专利（或专利申请）及550项以上的产品注册。这一资产组合在上一财年为全球50多个国家的客户创造了超过5亿美元的商品和服务销售额。Moolec首席财务官兼董事José López Lecube表示：“此次变革性的交易标志着Moolec发展的新阶段，使公司能够在一个更大组织架构中实现增长，并在多个层面释放协同效应。加入一个更大的组织将带来成本效益和显著的营收增长，同时也将推动产品组合多元化。此举还将扩大我们的投资人基础，为Moolec引入支持其新业务结构和多元化发展的新利益相关方。”最后，正如所通报的，Gastón Paladini先生将在2025年4月22日召开的Moolec特别股东大会（“EGM”）结束后，立即卸任首席执行官（CEO）、董事及董事会主席职务。重点摘要：原料创新：Moolec将继续研发其标志性的分子农业产品，如Piggy Sooy™和GLASO™，同时整合来自Nutrecon的Mycofood™，并统一纳入Eternal®品牌旗下。生物农业扩展：通过Bioceres集团，Moolec将提供面向再生农业的上游技术，包括生物投入品以及具气候韧性的种子，例如Rizobacter®、ProFarm®和HB4®性状种子。先进研发与服务：借助扩展后的基础设施，Moolec将通过Agrality®和Synbio Powerlabs®品牌分别由Bioceres集团和Nutrecon控股或共同控股提供研发、合同开发与制造组织（CDMO）以及法规合规等服务。新兴技术与设备：公司还将拓展其在谷物与生物质转化相关的新兴技术领域的布局，特别是在生物材料方面；此外，还将探索农机设备的新概念，结合材料科学、电动化与自动化。这些前沿机会正由Gentle Tech与Bioceres集团旗下子公司推动发展。运营协同效应：本次业务合并预计将带来显著的成本协同效应及一体化管理架构，相关内容将在交易完成时或此前公布。时间表与审批事项本次业务合并已获所有参与交易实体董事会的一致批准。预计将在2025年第二季度或之后完成，前提包括Moolec完成其反向股票拆分程序以及公司注册地迁移至开曼群岛，同时还需满足其他惯常的交割条件与监管审批要求。其中也包括Moolec股东在特别股东大会上对与本次业务合并相关提案的批准。鉴于该交易最初由约70%的Moolec现有股东提议，公司预计将获得强有力的股东支持。本次业务合并将通过股权交换方式完成。Bioceres集团的股东将交出其在Bioceres集团的股份，并获得最多80,590,280股Moolec股票作为交换。Nutrecon 100%股份和Gentle Tech 50%股份的股东将交出其在上述两家实体中的持股，并作为交换获得6,475,000股Moolec股票以及5,000,000份Moolec认股权证，认购价为每份$2.00，具体数量将依据反向拆股结果进行调整。交换比例的内在价值以及认股权证每份2美元的行权价，不仅相较于Moolec当前股价具有显著溢价，还代表着一次组建农业行业最具实力的上市公司的独特机会。出资实体及资产概况 出资实体包括Bioceres集团及其子公司、Nutrecon及其子公司，以及Gentle Tech及其子公司。Bioceres 集团Bioceres Crop Solutions Corp. (NASDAQ: BIOX)Bioceres是一家全面整合的作物生产力解决方案提供商，涵盖种子和微生物农业投入品的专利技术，以及新一代的作物营养与作物保护解决方案。 该公司开发了HB4®技术，该技术可赋予大豆和小麦应对气候变化的能力，使作物能够耐受干旱和土壤盐碱等不利条件。 此外，Bioceres拥有并授权超过570项产品，并在美国、加拿大、巴西、阿根廷及其他国家拥有约750项专利和专利申请。Bioceres Tech Services (Agrality® 与 Inmet)Agrality®是一家全球农业服务提供商，面向全球农业产业公司提供服务。其服务范围全面，涵盖种子生产与研发、田间试验及法规合规支持，为客户提供端到端的解决方案。Agrality的重要资产包括先进的种子生产设施，确保高质量种子的开发与生产。Inmet专注于农业工业废弃物的生物转化，为农业领域提供可持续的废弃物管理解决方案。公司运用创新技术将农业废弃物转化为有价值的产品。此外，Inmet也从事生物塑料的生产与评估，致力于开发环保替代传统塑料的可持续材料。Nutrecon (Synbio Powerlabs®)总部位于芬兰赫尔辛基的Synbio Powerlabs®是一家创新型早期生物技术公司，专注于可持续性真菌来源原料的研发与生产。公司拥有先进的实验室和从中试到工业规模的精密发酵设施，在运营模式上独具一格，兼具研发技术组织（RTO）与合同开发与生产组织（CDMO）的双重职能。这一双重角色使Synbio Powerlabs®能够无缝衔接尖端生物技术研究与现实工业应用，加速新型生物基产品的商业化。其主打产品线以Eternal®品牌销售，涵盖多种由真菌提取的高质量、可持续性原料，服务于多个行业与应用场景。Gentle Tech（G-FAS与Gentle Farming）一家前沿技术公司，致力于开发可持续的自动化农业设备。专注于通过材料科学、信息技术和替代能源的创新来降低环境影响，以最大限度提高效率并减少碳足迹。其商业模式包括G-FAS（直接向农民销售超轻型收割头）和Gentle Farming（开发用于自主作业和智能管理的农业机械）。前瞻性声明本新闻稿包含“前瞻性声明”。前瞻性声明可能通过使用诸如“预测”，“打算”，“寻求”，“目标”，“预期”，“相信”，“期望”，“估计”，“计划”，“展望”和“项目”等表达方式来识别，以及其他类似的表达，预测或指示未来事件或趋势，或者不是历史事实的陈述。就Moolec业务的表现，前景，收入和其他方面的前瞻性声明是关于未来事件的预测，预测和其他声明，这些预测，预测和其他声明基于目前的期望和假设，并因此而受到风险和不确定性的影响。尽管我们相信我们对本新闻稿中包含的每一项前瞻性声明都有合理的依据，但我们提醒您，这些声明是基于一系列事实和因素，我们无法确定其中的情况。我们无法向您保证本新闻稿中的前瞻性声明将证明准确。这些前瞻性声明受到许多重大风险和不确定性的影响，可能导致实际结果与预期结果有重大差异，其中包括但不限于，适用法律或法规的变化，Moolec可能受到经济，商业和/或其他竞争因素的不利影响，与Moolec业务规模扩大相关的成本以及其他风险和不确定性，包括在Moolec提交给美国证券交易委员会（“SEC”）的20-F表格的“风险因素”标题下列出的风险因素，以及Moolec向SEC提交的其他文件。如果其中一个或多个风险或不确定因素成为现实，或者Moolec的任何假设被证明不正确，实际结果可能在很大程度上与这些前瞻性声明中预期的结果不同。我们不承担更新或修订任何前瞻性声明的义务，无论是基于新信息，未来事件还是其他原因，除非在适用的证券法律下可能要求。因此，您不应过分依赖这些声明。联系信息Press & Media: comms@moolecscience.comInvestor Relations: ir@moolecscience.com资料来源: Moolec Science SA相关文件:Moolec Science Enters into Transformational Transaction Expanding Across Multiple Technology Platforms.pdf Copyright 2025 亚太商讯 via SeaPRwire.com.